Arrowhead Pharmaceuticals vs Immunocore
Arrowhead Pharmaceuticals reported revenue of $451 million in fiscal 2026, about the same as Immunocore's $400 million in fiscal 2025. Arrowhead Pharmaceuticals' revenue fell 45.6% in its latest year, and Immunocore's grew 28.9%. Arrowhead Pharmaceuticals had an operating margin of -156.9%, against -11.3% at Immunocore. Free cash flow was −$284 million at Arrowhead Pharmaceuticals and −$15 million at Immunocore. Their fiscal years end in different months (September 30 and December 31), so the periods don't line up exactly.
Side by side
| Arrowhead Pharmaceuticals | Immunocore | |
|---|---|---|
| Latest fiscal year | FY2026, Sep 30, 2026 | FY2025, Dec 31, 2025 |
| Revenue | $451M | $400M |
| Revenue growth | −45.6% | 28.9% |
| Revenue growth a year, last 5 years | 26.7% | — |
| Gross margin | — | 98.7% |
| Operating margin | −156.9% | −11.3% |
| Net margin | −160.6% | −8.9% |
| Free cash flow | −$284M | −$15M |
| Free cash flow margin | −63.0% | −3.8% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 5.9% | 0.7% |
| Last close | $43.65 | $26.63 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | sold $37.3 million | sold $5.6 million |
| Piotroski F-score | 2 of 8 | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Arrowhead PharmaceuticalsImmunocore
Operating margin
Percent of revenue
Arrowhead PharmaceuticalsImmunocore
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Arrowhead PharmaceuticalsImmunocore
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Arrowhead Pharmaceuticals and Immunocore pages.